STOCK TITAN

GT Biopharma Inc - GTBP STOCK NEWS

Welcome to our dedicated news page for GT Biopharma (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on GT Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GT Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GT Biopharma's position in the market.

Rhea-AI Summary
GT Biopharma, Inc. announces progress with FDA for GTB-3650 and plans for Phase 1 trial, submission of IND for GTB-5550, and cash position of $14 million. Financially, the company had a decrease in R&D and G&A expenses, an increase in other income, and reported a reduced net loss for Q4 and full-year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
-
Rhea-AI Summary
GT Biopharma, Inc. announces a reverse stock split at a ratio of 1-for-30 to regain compliance with the Minimum Bid Price Requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. The reverse stock split reduces the number of outstanding common stock shares from approximately 41,419,000 shares to approximately 1,380,633 shares. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024, and the Company's common stock will begin trading on a post-split basis at the market open on February 5, 2024 under the symbol 'GTBP'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2715.15%
Tags
-
Rhea-AI Summary
GT Biopharma, Inc. (NASDAQ: GTBP) has submitted an Investigational New Drug (IND) application for GTB-3650, a 2nd generation nanobody TriKE® for the treatment of CD33+ leukemia. The company aims to advance this molecule into the clinic in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.91%
Tags
none
Rhea-AI Summary
GT Biopharma announces positive preclinical data for GTB-5550 in prostate cancer. The TriKE molecule demonstrated improved tumor control and NK cell cytotoxicity, even in resistant lines and hypoxia. The findings support the TriKE technology and its potential in prostate cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GT Biopharma announces third quarter 2023 results, plans to submit IND for GTB-3650 in Q4 2023, and has cash of $16 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.28%
Tags
GT Biopharma Inc

Nasdaq:GTBP

GTBP Rankings

GTBP Stock Data

5.38M
1.16M
10.42%
13.46%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Westlake Village

About GTBP

using our proprietary platform technology, gt biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary nk cell engager (trike) platform technology. (nasdaq: gtbp)